Share on StockTwits
 

Alexion Pharmaceuticals (NASDAQ:ALXN) CFO Vikas Sinha unloaded 3,552 shares of the stock on the open market in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $154.47, for a total value of $548,677.44. Following the completion of the sale, the chief financial officer now directly owns 129,775 shares of the company’s stock, valued at approximately $20,046,344. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on ALXN. Analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday. They now have a $170.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $150.00 to $185.00 in a research note to investors on Friday, January 31st. Finally, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $106.00 to $145.00 in a research note to investors on Friday, January 31st. They now have a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $153.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.10% during mid-day trading on Wednesday, hitting $154.49. 1,416,879 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $169.98. The stock has a 50-day moving average of $137.4 and a 200-day moving average of $120.4. The company has a market cap of $30.346 billion and a price-to-earnings ratio of 123.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.87 EPS for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.